Search

Your search keyword '"Jackson, Graham"' showing total 3,665 results
Start Over Author "Jackson, Graham"

Refine your results

more »

more »

more »

more »

more »

more »
3,665 results on '"Jackson, Graham"'

3. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

Author

Stölzel, Friedrich, Fordham, Sarah E, Nandana, Devi, Lin, Wei-Yu, Blair, Helen J, Elstob, Claire J, Bell, Hayden L, Mohr, Brigitte, Ruhnke, Leo, Kunadt, Desiree, Dill, Claudia, Allsop, Daniel A, Piddock, Rachel E, Soura, Emmanouela-Niki, Park, Catherine Vida, Fadly, Mohd, Rahman, Thahira, Alharbi, Abrar A, Wobus, Manja, Altmann, Heidi, Röllig, Christoph, Wagenführ, Lisa, Jones, Gail L, Menne, Tobias, Jackson, Graham H, Marr, Helen J, Fitzgibbon, Jude, Onel, Kenan, Meggendorfer, Manja, Robinson, Amber, Bziuk, Zuzanna, Bowes, Emily, Heidenreich, Olaf, Haferlach, Torsten, Villar, Sara, Ariceta, Beñat, Diaz, Rosa Ayala, Altschuler, Steven J, Wu, Lani, Prosper, Felipe, Montesinos, Pau, Martinez-Lopez, Joaquin, Bornhäuser, Martin, and Allan, James M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Hematology, Genetics, Pediatric, Pediatric Cancer, Rare Diseases, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Humans, Mice, Animals, Azacitidine, Leukemia, Myeloid, Acute, Kaplan-Meier Estimate, Mutation, DNA-Binding Proteins, Dioxygenases, Leukemias, Molecular genetics, Biomedical and clinical sciences, Health sciences
Abstract

Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine but acutely sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting in long-term morphological remission. Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5'-Aza compared with cells with monoallelic mutations. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first-line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for patients with cancer.

Published
2023

9. Final Report for Creative 3D Plant Optimization (C3PO) System

Author

Timothy Taylor, Jackson Graham, Scott Jones, Iren Bencze, Ryan Summers, Shelby Berrett, Carter Bodnar, Joanna Boyd, Jake Brockwell, Rebecca Brown, Emily Burgett, Kaitlin Burnash, Logan Crawford, Camille Daniels, Amanda Dennis, Jaci Fielding, Crystal Fowler, Dallin Gividen, Camren Hansen, Skyler Heiner, Brandon Furman, Cameron LeBaron, Nicholas Narrell, Ty Nicholas, Adreann Peel, Andrew Poulos, David Redd, and Joshua Wallace

Subjects
Life Sciences (General), Lunar and Planetary Science and Exploration, Computer Programming and Software
Abstract

Utah State University (USU) and the University of Alabama’s (UA) X-Hab design project created a 3D printed substrate to facilitate plant growth in a microgravity environment. The design team proposed a 3D printed substrate that would allow the plants to have a root support matrix, necessary oxygen flow, and a passive water and nutrient delivery system. This substrate was designed to easily integrate into NASA’s Veggie and Advanced Plant Habitat platforms. 3D printed components are easily replaceable at a relatively low cost. In addition, since research and development has moved to using 3D printers in space, any needed garden components for the blocks could be easily re-printed while in orbit.

Published
2023

10. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

Author

Jones, John R., Cairns, David A., Menzies, Tom, Pawlyn, Charlotte, Davies, Faith E., Sigsworth, Rachel, Brioli, Annamaria, Jenner, Matthew W., Kaiser, Martin F., Olivier, Catherine, Reed, Molly, Drayson, Mark T., Owen, Roger G., Boyd, Kevin D., Cook, Gordon, Morgan, Gareth J., and Jackson, Graham H.

Published
2023
Full Text
View/download PDF

14. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author

Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhäuser, Martin, Röllig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenführ, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, José, Gómez-Seguí, Inés, Cluzeau, Thomas, Moreilhon, Chimène, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Hervé, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsán, Szilvia, Bödör, Csaba, Stölzel, Friedrich, Onel, Kenan, and Allan, James M.

Published
2022
Full Text
View/download PDF

18. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Sonneveld, Pieter, Facon, Thierry, San-Miguel, Jesus, Avet-Loiseau, Hervé, Mohty, Mohamad, Mateos, Maria-Victoria, Moreau, Philippe, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Engelhardt, Monika, Driessen, Christoph, Cook, Gordon, Dimopoulos, Melitios A, Gay, Francesca, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Schreder, Martin, Abildgaard, Niels, Hajek, Roman, Zojer, Niklas, Kastritis, Efstathios, Broijl, Annemiek, Schjesvold, Fredrik, Boccadoro, Mario, and Terpos, Evangelos

Published
2021
Full Text
View/download PDF

22. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

Author

Croft, James, Ellis, Sidra, Sherborne, Amy L., Sharp, Kim, Price, Amy, Jenner, Matthew W., Drayson, Mark T., Owen, Roger G., Chown, Sally, Lindsay, Jindriska, Karunanithi, Kamaraj, Hunter, Hannah, Gregory, Walter M., Davies, Faith E., Morgan, Gareth J., Cook, Gordon, Atanesyan, Lilit, Savola, Suvi, Cairns, David A., Jackson, Graham, Houlston, Richard S., and Kaiser, Martin F.

Published
2021
Full Text
View/download PDF

23. Progression-free survival as a surrogate endpoint in myeloma clinical trials:an evolving paradigm

Author

Pawlyn, Charlotte, Schjesvold, Fredrik H., Cairns, David A., Wei, L. J., Davies, Faith, Nadeem, Omar, Abdulhaq, Haifaa, Mateos, Maria Victoria, Laubach, Jacob, Weisel, Katja, Ludwig, Heinz, Rajkumar, S. Vincent, Sonneveld, Pieter, Jackson, Graham, Morgan, Gareth, Richardson, Paul G., Pawlyn, Charlotte, Schjesvold, Fredrik H., Cairns, David A., Wei, L. J., Davies, Faith, Nadeem, Omar, Abdulhaq, Haifaa, Mateos, Maria Victoria, Laubach, Jacob, Weisel, Katja, Ludwig, Heinz, Rajkumar, S. Vincent, Sonneveld, Pieter, Jackson, Graham, Morgan, Gareth, and Richardson, Paul G.

Abstract

Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients. Surrogate endpoints of OS, such as progression-free survival (PFS) and response to treatment, have contributed to approval decisions by the Food and Drug Administration (FDA) and European Medicines Agency as endpoints demonstrating clinical benefit, and the FDA has recently supported the use of minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma. This review aims to address situations in which the use of PFS as a surrogate endpoint warrants careful interpretation especially for specific subgroups of patients and considers ways to ensure that studies can be designed to account for possible discordance between PFS and OS. The utility of subgroup analyses, including the potential for those not pre-specified, to identify target populations for new agents is also discussed.

Published
2024

25. Transforming Outcomes in Multiple Myeloma With Antibody-Based Regimens

Author

Jackson, Graham

Subjects
Johnson & Johnson, Sanofi S.A., Continuing medical education, Multiple myeloma, Carfilzomib, Pharmaceutical industry, Health
Abstract

FACULTY, STAFF, AND PLANNERS' DISCLOSURES In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by [...]

Published
2021

29. Genomic Classification and Individualized Prognosis in Multiple Myeloma

Author

Maura, Francesco, primary, Rajanna, Arjun Raj, additional, Ziccheddu, Bachisio, additional, Poos, Alexandra M., additional, Derkach, Andriy, additional, Maclachlan, Kylee, additional, Durante, Michael, additional, Diamond, Benjamin, additional, Papadimitriou, Marios, additional, Davies, Faith, additional, Boyle, Eileen M., additional, Walker, Brian, additional, Hultcrantz, Malin, additional, Silva, Ariosto, additional, Hampton, Oliver, additional, Teer, Jamie K., additional, Siegel, Erin M., additional, Bolli, Niccolò, additional, Jackson, Graham H., additional, Kaiser, Martin, additional, Pawlyn, Charlotte, additional, Cook, Gordon, additional, Kazandjian, Dickran, additional, Stein, Caleb, additional, Chesi, Marta, additional, Bergsagel, Leif, additional, Mai, Elias K., additional, Goldschmidt, Hartmut, additional, Weisel, Katja C., additional, Fenk, Roland, additional, Raab, Marc S., additional, Van Rhee, Fritz, additional, Usmani, Saad, additional, Shain, Kenneth H., additional, Weinhold, Niels, additional, Morgan, Gareth, additional, and Landgren, Ola, additional

Published
2024
Full Text
View/download PDF

30. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Boccadoro, Mario, Moreau, Philippe, San-Miguel, Jesus, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Facon, Thierry, Driessen, Christoph, Hajek, Roman, Dimopoulos, Melitios A., Gay, Francesca, Avet-Loiseau, Hervé, Terpos, Evangelos, Zojer, Niklas, Mohty, Mohamad, Mateos, Maria-Victoria, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, Engelhardt, Monika, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Abildgaard, Niels, Bringhen, Sara, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

31. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

32. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author

Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhäuser, Martin, Röllig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenführ, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, José, Gómez-Seguí, Inés, Cluzeau, Thomas, Moreilhon, Chimène, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Hervé, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsán, Szilvia, Bödör, Csaba, Stölzel, Friedrich, Onel, Kenan, and Allan, James M.

Published
2021
Full Text
View/download PDF

34. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

35. Donor monocyte-derived macrophages promote human acute graft-versus-host disease

Author

Jardine, Laura, Cytlak, Urszula, Gunawan, Merry, Reynolds, Gary, Green, Kile, Wang, Xiao-Nong, Pagan, Sarah, Paramitha, Maharani, Lamb, Christopher A., Long, Anna K., Hurst, Erin, Nair, Smeera, Jackson, Graham H., Publicover, Amy, Bigley, Venetia, Haniffa, Muzlifah, Simpson, A.J., and Collin, Matthew

Subjects
Macrophages -- Analysis, Skin -- Analysis -- Genetic aspects, Gene expression -- Analysis -- Genetic aspects, T cells -- Genetic aspects -- Analysis, Health care industry
Abstract

Myelopoiesis is invariably present and contributes to pathology in animal models of graft-versus-host disease (GVHD). In humans, a rich inflammatory infiltrate bearing macrophage markers has also been described in histological studies. In order to determine the origin, functional properties, and role in pathogenesis of these cells, we isolated single-cell suspensions from acute cutaneous GVHD and subjected them to genotype, transcriptome, and in vitro functional analysis. A donor-derived population of [CD11c.sup.+][CD14.sup.+] cells was the dominant population of all leukocytes in GVHD. Surface phenotype and NanoString gene expression profiling indicated the closest steady-state counterpart of these cells to be monocyte-derived macrophages. In GVHD, however, there was upregulation of monocyte antigens SIRP[alpha] and S100A8/9 transcripts associated with leukocyte trafficking, pattern recognition, antigen presentation, and costimulation. Isolated GVHD macrophages stimulated greater proliferation and activation of allogeneic T cells and secreted higher levels of inflammatory cytokines than their steady-state counterparts. In HLA-matched mixed leukocyte reactions, we also observed differentiation of activated macrophages with a similar phenotype. These exhibited cytopathicity to a keratinocyte cell line and mediated pathological damage to skin explants independently of T cells. Together, these results define the origin, functional properties, and potential pathogenic roles of human GVHD macrophages., Introduction Acute graft-versus-host disease (GVHD) affects up to 50% of patients receiving allogeneic bone marrow transplantation (BMT) and remains a leading cause of morbidity and mortality (1, 2). GVHD most [...]

Published
2020
Full Text
View/download PDF

39. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

41. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry

Author

Giles, Hannah, primary, Drayson, Mark, additional, Kishore, Bhuvan, additional, Pawlyn, Charlotte, additional, Kaiser, Martin, additional, Cook, Gordon, additional, de Tute, Ruth, additional, Owen, Roger, additional, Cairns, David, additional, Menzies, Tom, additional, Davies, Faith, additional, Morgan, Gareth, additional, Pratt, Guy, additional, and Jackson, Graham, additional

Published
2023
Full Text
View/download PDF

42. P-357 Individualized risk in newly diagnosed multiple myeloma

Author

Maura, Francesco, primary, Rajanna, Arjun, additional, Ziccheddu, Bachisio, additional, Derkach, Andriy, additional, Poos, Alexandra, additional, Maclachlan, Kylee, additional, Boyle, Eileen, additional, Hultcrantz, Malin, additional, Silva, Ariosto, additional, Jackson, Graham, additional, Kaiser, Martin, additional, Pawlyn, Charlotte, additional, Cook, Gordon, additional, Bergsagel, Leif, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Fenk, Roland, additional, Mai, Elias, additional, Raab, Marc, additional, van Rhee, Frits, additional, Usmani, Saad, additional, Shain, Ken, additional, Weinhold, Niels, additional, Morgan, Gareth, additional, and Landgren, Ola, additional

Published
2023
Full Text
View/download PDF

44. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Author

Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Philippe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, and Morgan, Gareth J.

Published
2018
Full Text
View/download PDF

45. The development of Case Assessment and Interpretation (CAI) in forensic science

Author

Jackson, Graham and Bremner, David

Subjects
363.25
Abstract

Expert opinion has been, and still is, of undoubted assistance in the investigation of crime and the administration of criminal justice. It has also been the cause of a number of celebrated miscarriages of justice. Technological advances and greater investment in forensic science resources in the latter half of the 20 century meant that forensic science could be applied to many more cases than ever before. It also meant that forensic scientists had to meet new challenges in the way they formed and expressed opinions about their findings. The creation of a commercial market for forensic science in the 1990s in England and Wales put additional pressures on suppliers to provide value-for-money for their customers. In an attempt to satisfy the potentially conflicting demands of providing robust, reliable opinion and of giving value-for-money, a novel process called Case Assessment and Interpretation (CAI), based on the underlying logic of Bayes Theorem and the use of likelihood ratios, was proposed in 1998 as a model of good practice in forensic science. Over the course of the next 12 years, the model process was applied to most main-stream forensic science disciplines and, as a result, the ideas were refined and fresh insights on the nature of expertise were gained. This thesis describes the background to the initial development of the CAI model, sets out subsequent improvements, demonstrates how the model may have helped avoid misleading opinion being given and considers the current status of CAI. The conclusion of the thesis is that assessment of likelihood ratios, within the framework of the Case Assessment and Interpretation model, does provide a philosophical, yet practical, means of delivering robust, reliable opinion and value-for-money.

Published
2011

49. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Author

Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith, Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Phillipe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, and Morgan, Gareth

Published
2019
Full Text
View/download PDF

50. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease

Author

Nehra, Ajay, Jackson, Graham, Miner, Martin, Billups, Kevin L, Burnett, Arthur L, Buvat, Jacques, Carson, Culley C, Cunningham, Glenn R, Ganz, Peter, Goldstein, Irwin, Guay, Andre T, Hackett, Geoff, Kloner, Robert A, Kostis, John, Montorsi, Piero, Ramsey, Melinda, Rosen, Raymond, Sadovsky, Richard, Seftel, Allen D, Shabsigh, Ridwan, Vlachopoulos, Charalambos, and Wu, Frederick CW

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease, Cardiovascular, Contraception/Reproduction, Prevention, Urologic Diseases, Good Health and Well Being, Cardiovascular Diseases, Erectile Dysfunction, Exercise Tolerance, Humans, Life Style, Male, Practice Guidelines as Topic, Primary Prevention, Referral and Consultation, Risk Assessment, Risk Reduction Behavior, Sexual Behavior, Testosterone, Medical and Health Sciences, Biomedical and clinical sciences
Abstract

The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative tradition dedicated to optimizing sexual function and preserving cardiovascular health. The third Princeton Consensus met November 8 to 10, 2010, and had 2 primary objectives. The first objective focused on the evaluation and management of cardiovascular risk in men with erectile dysfunction (ED) and no known cardiovascular disease (CVD), with particular emphasis on identification of men with ED who may require additional cardiologic work-up. The second objective focused on reevaluation and modification of previous recommendations for evaluation of cardiac risk associated with sexual activity in men with known CVD. The Panel's recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing the use of exercise ability and stress testing to ensure that each man's cardiovascular health is consistent with the physical demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD, which may be asymptomatic and may benefit from cardiovascular risk reduction.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results